Pathology Unit, S. Orsola Malpighi Hospital, Bologna University, Bologna, Italy.
Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.
Acta Histochem. 2020 Feb;122(2):151498. doi: 10.1016/j.acthis.2019.151498. Epub 2019 Dec 27.
Dermatofibroma (BFH), atypical fibroxanthoma (AFX) and dermal pleomorphic sarcoma (DPS) are skin-based soft-tissue neoplasms of uncertain lineage. They are classified as "fibrohistiocytic" neoplasms, even if the World Health Organization stated that this term connotes a polymorphic group of lesions that histologically resemble fibroblasts and histiocytes. It is well-known that this group of lesions shows a "fibro-histiocytic-dendritic" and/or a "myofibroblastic" phenotype, even within the same lesion. We studied the expression of cathepsin-k in 34 cases (25 BFH, 5 AFX, 4 DPS) with a broad panel of antibodies. 20 cases (5 dermatofibrosarcoma protuberans, 5 melanomas, 5 basal cell carcinomas, 5 squamous cell carcinomas) were chosen as controls. Although our results need to be validated, they support a myofibroblastic and/or partial myofibroblastic ("proto-myofibroblastic") phenotype and the lineage-plasticity of these neoplasms, highlighting the potential role of cathepsin-k in myofibroblastic trans-differentiation. Cathepsin-k proved to be an additional immunoistochemical marker potentially useful in the diagnostic algorithm.
皮肤纤维瘤 (BFH)、非典型纤维黄色瘤 (AFX) 和真皮多形性肉瘤 (DPS) 是起源不明的皮肤软组织肿瘤。它们被归类为“纤维组织细胞”肿瘤，尽管世界卫生组织指出，这个术语暗示了一组在组织学上类似于成纤维细胞和组织细胞的多形性病变。众所周知，这群病变表现出“纤维组织细胞-树突状”和/或“肌纤维母细胞”表型，即使在同一病变中也是如此。我们使用广泛的抗体 panel 研究了 34 例病例（25 例皮肤纤维肉瘤、5 例非典型纤维黄色瘤、4 例真皮多形性肉瘤）中组织蛋白酶 K 的表达情况。选择 20 例作为对照（5 例隆突性皮肤纤维肉瘤、5 例黑色素瘤、5 例基底细胞癌、5 例鳞状细胞癌）。虽然我们的结果需要进一步验证，但它们支持这些肿瘤的肌纤维母细胞和/或部分肌纤维母细胞（“原肌纤维母细胞”）表型和谱系可塑性，并强调组织蛋白酶 K 在肌纤维母细胞转分化中的潜在作用。组织蛋白酶 K 被证明是一种潜在有用的免疫组织化学标志物，可用于诊断算法。
